[ONTX] Onconova Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.39 Change: 0.03 (1.27%)
Ext. hours: Change: 0 (0%)

chart ONTX

Refresh chart

Strongest Trends Summary For ONTX

ONTX is in the medium-term down -49% in 6 months. In the long-term up 336911% in 19 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -8.8% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-156.2% ROE-487.72% ROI
Current Ratio3.38 Quick Ratio Long Term Debt/Equity Debt Ratio0.92
Gross Margin Operating Margin-12282.7% Net Profit Margin-12279.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-9.85 M Gross Profit
Net Profit-12.34 M Operating Profit-12.35 M Total Assets36.71 M Total Current Assets36.35 M
Total Current Liabilities10.76 M Total Debt Total Liabilities24.95 M Total Revenue110 K
Technical Data
High 52 week10.59 Low 52 week0.35 Last close2.15 Last change-8.9%
RSI62.57 Average true range0.28 Beta0.12 Volume18.76 K
Simple moving average 20 days-5.97% Simple moving average 50 days-37.56% Simple moving average 200 days-54.13%
Performance Data
Performance Week-8.12% Performance Month-31.31% Performance Quart-63.93% Performance Half-69.17%
Performance Year23.56% Performance Year-to-date1.9% Volatility daily9.24% Volatility weekly20.66%
Volatility monthly42.35% Volatility yearly146.7% Relative Volume157.7% Average Volume102.98 K
New High New Low

News

2019-03-19 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

2019-03-12 07:30:00 | Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA

2019-02-04 08:00:00 | Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City

2019-01-31 07:30:00 | Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City

2019-01-22 07:30:00 | Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL

2019-01-16 13:08:04 | Bucks County biopharm firm names new CEO

2019-01-15 17:15:00 | Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer

2019-01-02 07:30:00 | Onconova Submits Special Protocol Assessment SPA to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine Vidaza® for First-Line Myelodysplastic Syndromes MDS

2018-12-31 07:30:00 | Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco

2018-12-10 07:30:00 | Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel

2018-12-03 07:30:00 | Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine Vidaza® in Myelodysplastic Syndromes MDS at the 2018 ASH Annual Meeting

2018-11-13 15:41:27 | Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT

2018-11-13 07:00:00 | Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018

2018-11-07 08:30:00 | Onconova Welcomes Richard Ric Woodman, M.D., as Chief Medical Officer CMO

2018-11-06 10:30:03 | Onconova Therapeutics ONTX May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2018-11-05 08:30:00 | Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes MDS at the 2018 ASH Annual Meeting & Exposition

2018-11-01 08:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results

2018-10-29 08:30:00 | Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark

2018-10-17 08:30:00 | Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib

2018-10-10 08:30:00 | Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco

2018-09-27 08:00:00 | Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences

2018-09-26 12:12:17 | Bucks County biopharm firm implements reverse stock split

2018-09-25 09:16:13 | Onconova Therapeutics Announces Reverse Stock Split

2018-08-21 08:30:00 | Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes MDS to South America with Pint Pharma

2018-08-15 10:05:53 | Edited Transcript of ONTX earnings conference call or presentation 14-Aug-18 1:00pm GMT

2018-08-14 08:00:00 | Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018

2018-08-14 07:00:00 | Onconova Therapeutics Inc. to Host Earnings Call

2018-08-07 08:00:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results

2018-07-17 07:25:00 | Free Technical Research on OPKO Health and Three More Biotech Equities

2018-06-21 08:00:00 | Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D.

2018-06-07 08:30:00 | Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association

2018-05-29 08:00:00 | Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational

2018-05-25 19:21:18 | Who Are The Top Investors In Onconova Therapeutics Inc NASDAQ:ONTX?

2018-05-22 07:00:00 | Free Technical Insights on OPKO Health and Three Other Biotech Stocks

2018-05-15 18:30:54 | Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT

2018-05-15 08:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018

2018-05-15 07:31:13 | Analysts Expect Breakeven For Onconova Therapeutics Inc NASDAQ:ONTX

2018-05-09 08:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results

2018-05-03 08:00:00 | Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018

2018-05-01 20:10:14 | Onconova Therapeutics Inc NASDAQ:ONTX: Does The Earnings Decline Make It An Underperformer?

2018-05-01 18:33:47 | Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering

2018-04-27 06:00:00 | Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering

2018-04-19 08:30:00 | Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting

2018-03-26 08:30:00 | Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium

2018-03-15 08:00:00 | Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018

2018-03-09 12:13:37 | Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT

2018-03-08 08:00:00 | Onconova Therapeutics Inc. to Host Earnings Call

2018-03-06 08:30:00 | Onconova Therapeutics to Present at the 30th Annual Roth Conference in March

2018-03-05 08:00:00 | Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America

2018-03-04 10:00:00 | Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research AACR Epigenetics Conference